Michael H. Davidson to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Michael H. Davidson has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.161
-
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013 May-Jun; 7(3 Suppl):S11-5.
Score: 0.107
-
ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec; 237(2):705-10.
Score: 0.030
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
Score: 0.024